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1 
BIO MIMETIC POLYMERS AND USES 
THEREOF 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
2 
Therefore, it is an object of the invention to provide bio-
mimetic polymers, particularly biodegradable biomimetic 
polymers. 
It is another object to provide biomimetic polymer matri-
ces. 
It is still another object to provide biomimetic polymers for 
use in tissue engineering. 
It is a further object to provided matrices for delivery of 
bioactive factors. 
This application is a filing under 35 U.S.C. § 371 of PCT/ 
US2007 /072946 filed with the U.S. Receiving Office of the 
Patent Cooperation Treaty on Jul. 6, 2007, and claims priority 
to and benefit ofU. S. Provisional Application No. 60/819 ,219 
filed on Jul. 7, 2006 by Yadong Wang, and where permissible 
is incorporated by reference in its entirety. 
10 
It is yet another object to provide compositions and meth-
ods for promoting wound healing and cell differentiation. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 15 
It is a further object to provide biomimetic polymers for 
delivering therapeutic agents including nucleic acids and 
growth factors. 
SUMMARY 
This invention was made with Government Support under 
Agreement R21-EB008565-01Al, awarded by the National 
Institutes of Health. The Government has certain rights in the 
invention. 
Biodegradable polymers incorporating biomolecules are 
provided. Exemplary polymers are formed by polymerizing 
biomolecules having a functional group such as a primary 
20 amine with diglycidyl esters. One embodiment provides a 
polymer according to the following formula: 
BACKGROUND 
The use of synthetic polymers in medicine during World 25 
War II marked the beginning of biomaterials science. These 
materials enabled many new medical treatments that ben-
efited tens of millions of people annually. The advancement 
of modem medicine demands materials with biological func-
tions, which are lacking in most of the current biomaterials in 30 
clinical use. Proper physiological functions rely on a diverse 
array of materials, the main building blocks of which are 
amino acids. Numerous bioactivities rely on the versatile 
amino acid side chains. Further, amino acid derivatives such 
as dopamine and serotonin are vital signaling molecules in 35 
biological processes. Current approaches to functional bio-
materials including protein engineering and self-assembled 
synthetic polypeptides have limited diversity in material 
properties and functions (most of these polypeptides are 
hydrogels). Combinatorial chemistry can greatly increase 40 
material diversity; however this strategy has yet to be applied 
to biomolecules. The resulting biomolecules can be used in a 
variety of applications, including but not limited to medical 
treatments. 
State-of-the-art medical treatments still have limited sue- 45 
wherein R1 is any alkyl, cycloalkyl, heterocycloalkyl, aryl, 
heteroaryl, or heterocycle optionally substituted with halide, 
alcohol, ether, thioether, tertiary amine, ketone, ester, and 
amide; 
R2 is any alkyl, cycloalkyl, aryl, heteroaryl, optionally sub-
stituted with halide, alcohol, ether, thioether, tertiary amine, 
ketone, ester, and amide; 
R3 is a biomolecule bound to R2 via an amine bound; and 
n is ~1. 
In other embodiments, n>than 1,000, greater than 10,000 
or even greater than 1,000,000. 
In still other embodiments R1 can be polyethylene glycol, 
(CH12-CH2-0-)x, where x~l and less than 10,000. 
The polymers can be tailored for specific functions and 
uses by selecting specific biomolecules to be incorporated 
into the polymer. For example, neurotransmitters such as 
dopamine can be polymerized with diglycidyl esters to pro-
duce biodegradable polymers that stimulate or promote neu-
rite growth or outgrowth. Polymers incorporating neurotrans-
mitters can be used for treating neurological disorders. 
Another embodiment provides biodegradable polymers 
that serve as a delivery vehicle for nucleic acids. Arginine 
cess in restoring functions to nervous systems after a major 
assault. A promising solution to this challenge is to induce 
neurite sprouting and guide the regenerating nerve by appro-
priately-designed biomaterials. Biomimetic polymers with 
proper information content and functionality can direct 
appropriate cellular responses. One way to achieve biomim-
icry is to integrate biomolecules into polymers. Surface-teth-
ered neurotransmitters can activate the corresponding cellu-
lar receptors and neurotransmitters directly integrated into a 
biomimetic polymer can induce specific responses from neu-
rons. 
50 monomers can be polymerized with diglycidyl esters to pro-
duce polymers that carry a net positive charge under physi-
ological conditions. The positively charged polymer can 
interact with negatively charged nucleic acids to assist in 
delivering the nucleic acid to a cell. In certain aspects, the 
Numerous materials have been employed to promote nerve 
regeneration, with properties that range from hydrophobic to 
hydrophilic, degradable to non-degradable, resistant to pro-
tein adsorption to protein-based, and soft to hard. These mate-
rials often use laminin epitopes, such as Ile-Lys-Val-Ala-Val 
(SEQ ID NO: 1 ), to enhance neuron adhesion and sprouting. 
Because neural activities are highly regulated by neurotrans-
mitters, integrating them into materials may impart bioactiv-
55 polymer includes a protein transduction domain or cell pen-
etrating peptide. 
Still another embodiment provides biodegradable polymer 
matrix. The matrix can be formed by combining the disclosed 
polymers with heparin sulfate. The matrix can also contain 
60 bioactive factors bound or trapped in the matrix which can be 
released from the matrix when the matrix is administered to a 
host, for example when applied to a wound. 
BRIEF DESCRIPTION OF THE DRAWINGS 
ity to synthetic polymers and render them biomimetic. Such 65 
biomaterial may lead to an alternative approach to nerve FIG. lA shows exemplary functional biomaterials with 
degradable backbones and biomolecular side chains. The regeneration. 
US 8,529,928 B2 
3 
linkers can be synthesized from essentially any dicarboxylic 
acids enabling further control of properties such as hydrophi-
licity, structural rigidity, and spacing of biomolecules. 
FIG. lB shows a diagram indicating that the density of the 
biomolecules can be controlled by copolymerization with an 
"inert" primary amine. 
4 
F and Cl being preferred). A "lower alkyl group" is intended 
to mean alkyl group having from 1 to 4 carbon atoms in its 
chain. 
The term "biomolecule" refers to naturally produced mol-
ecules found in nature having one or more carbon atoms, 
including polymeric or nonpolymeric molecules. Represen-
tative biomolecules, include but are not limited to amino 
acids, nucleotides, purines, pyrimidines, lipids, carbohy-
drates, vitamins, proteoglycans, or combinations thereof. 
FIGS. 2A-B show absorption spectra of a representative 
biomaterial produced from 1,2-cyclohexyldiglycidyl ester 
and dopamine (PCD) and 1,2-cyclohexyldiglycidyl ester and 
tyrosine (PCY), respectively. 10 A "cycloalkyl group" is intended to mean a non-aromatic 
monovalentmonocyclic, bicyclic, ortricyclic radical contain-
ing 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14carbonringatoms, 
each of which may be saturated or unsaturated, and which 
may be unsubstituted or substituted by one or more suitable 
FIG. 3A is a graph showing degradation of PCD polymer 
expressed as a decrease of mass with time. Data expressed as 
mean±S.D. 
FIG. 3B is a series of bar graphs showing in vitro biocom-
patibility as indicated by the number of metabolically active 
cells on PCD relative to the controls. 
FIG. 3C is a series of bar graphs showing that cells dis-
played the highest differentiation level on PCD, and the level 
increased significantly with time. The controls did not induce 
more differentiation as the culture time increased. 
FIG. 3D is a series of bar graphs showing that the median 
neurite length increased substantially on PCD over the culture 
period. In comparison, the change on the control surfaces was 
statistically insignificant over the entire culture period. 
FIG. 3E is a line graph showing the distribution of neurite 
length on PCD versus the controls at day 5. 
FIG. 3F is a line graph showing the distribution ofneurite 
length on PCD versus the controls at day 7. The most probable 
neurite length on PCD was approximately 30 µmat day 5. The 
proportion of peaks ~50 µm increased significantly on day 7. 
FIG. 4 is a bar graph showing that NGF-primed PC12 cell 
growth rate on PCA resembled that of the controls. 
FIG. 5 is a bar graph showing that a biomaterial formed 
from arginine and 1,2-cyclohexyldiglycidyl (PCR) was safe 
to L2 cells at all concentrations tested. 
FIG. 6 shows an FTIR spectrum of PT-GREDV100 con-
firming the presence of specific functional groups in the poly-
mer. 
FIG. 7 is a bar graph showing the proliferation ofBaEPCs 
on gelatin-coated and P(TF 90-co-GREDV 10)-coated surfaces 
were similar as determined by MTT assay. Data expressed as 
mean±SD. 
FIG. 8 are bar graphs showing results of gel retardation 
assay which indicate complete retardation of plasmid DNA at 
NIP ratio between 411-811. From left to right: naked DNA, 
411, 811, 1211, and 1611 NIP ratios. 
15 substituents as defined below, and to which may be fused one 
or more heterocycloalkyl groups, aryl groups, or heteroaryl 
groups, which themselves may be unsubstituted or substi-
tuted by one or more substituents. 
A "heterocycloalkyl group" is intended to mean a non-
20 aromatic monocyclic, bicyclic, or tricyclic alkane, which is 
saturated or unsaturated, containing 3, 4, 5, 6, 7, 8, 9, 10, 11, 
12, 13, 14, 15, 16, 17, or 18 ring atoms, which includes 1, 2, 
3, 4, or 5 heteroatoms selected from nitrogen, oxygen, and 
sulfur, where the alkane is unsubstituted or substituted by one 
25 or more suitable substituents as defined below, and to which 
may be fused one or more cycloalkyl groups, aryl groups, or 
heteroaryl groups, which themselves may be unsubstituted or 
substituted by one or more appropriate substituents. 
An "aryl group" is intended to mean an aromatic monocy-
30 clic, bicyclic, or tricyclic alkane containing 6, 10, 14, or 18 
carbon ring atoms, which may be unsubstituted or substituted 
by one or more suitable substituents as defined below, and to 
which may be fused one or more cycloalkyl groups, hetero-
cycloalkyl groups, or heteroaryl groups, which themselves 
35 may be unsubstituted or substituted by one or more suitable 
substituents. 
A "heteroaryl group" is intended to mean an aromatic 
monocyclic, bicyclic, ortricyclic alkane containing 4, 5, 6, 7, 
8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 ring atoms, including 
40 1, 2, 3, 4, or 5 heteroatoms selected from nitrogen, oxygen, 
and sulfur, which may be unsubstituted or substituted by one 
or more suitable substituents as defined below, and to which 
may be fused one or more cycloalkyl groups, heterocy-
cloalkyl groups, or aryl groups, which themselves may be 
45 unsubstituted or substituted by one or more suitable substitu-
ents. 
FIG. 9 are bar graphs showing the release profile ofbFGF 
from PSR/HS networks. The amount of bFGF in the super- 50 
natant released from PSR/HS networks was measured over a 
period of time (t=l, 2, 5, and 10 days). This was done with or 
without the presence of Heparinase I and measured via 
ELISA analysis. 
A "heterocycle" is intended to mean a heteroaryl or het-
erocycloalkyl group (each of which, as defined above, are 
optionally substituted). 
II. Biomimetic Polymeric Compositions and Matrices 
One embodiment provides a platform for an extensive 
library of functional polymeric biomaterials with biomolecu-
lar side chains. The integration of a large variety of biomol-
ecules including amino acids and derivatives confers a wide 
DETAILED DESCRIPTION 
I. Definitions 
As used herein, the term "alkyl group" is intended to mean 
a straight- or branched-chain monovalent radical of saturated 
and/ or unsaturated carbon atoms and hydrogen atoms, such as 
methyl (Me), ethyl (Et), propyl, isopropyl, butyl, isobutyl, 
t-butyl, ethenyl, propenyl, butenyl, pentenyl, ethynyl propy-
nyl, butynyl, pentynyl, hexynyl, and the like, which may be 
unsubstituted (i.e., containing only carbon and hydrogen) or 
substituted by one or more suitable substituents as defined 
below (e.g., one or more halogens, such as F, Cl, Br, or I, with 
55 range of biological functions to the polymers, which may 
create a broad impact in biomedicine. The disclosed materials 
can be used for numerous applications including, but not 
limited to tissue engineering, wound repair, nerve repair, 
nerve regeneration, and drug delivery. The disclosed compo-
60 sitions can be produced by polymerizing virtually any bio-
molecules containing a primary amine group with diglycidyl 
esters. Diverse biomolecules such as amino acids, peptides, 
lipids and carbohydrates and their derivatives bestow a whole 
spectrum of biological functions to these novel materials, 
65 while the hybrid nature of the polymers incur a lower cost 
than materials like synthetic polypeptides (FIG. 1). Exem-
plary poly(aminoglycerol esters) (PAGE) have an ester back-
US 8,529,928 B2 
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bone and biomolecular side chains. Copolymerization of dif-
ferent types of biomolecules will further increase the 
diversity of these materials. Further, the density of the bio-
molecules can be controlled by copolymerization with an 
"inert" primary amine. 
In one embodiment, the molecular design is a result of four 
deliberations: (1) biodegradability: degradable material is 
favored because it will be absorbed by the body so as not to 
constrict the regenerating nerve; (2) degradable functional 10 
group: for example esters for versatile synthesis; (3) the poly-
merizable biomolecular functional group, for example a pri-
mary amine because of its ubiquitous presence among key 
biomolecules, secondary amines and alcohol groups can also 15 
be used; ( 4) polymerization mechanism, for example Michael 
Addition due to its mild reaction conditions. The R in the 
linkers can be synthesized from essentially any dicarboxylic 
acids enabling further control of the properties such as hydro-
6 
Another embodiment provides a polymer according to the 
following formula: 
wherein R1 is C2 -C8 alkyl, cycloalkyl, heterocycloalkyl, 
aryl, heteroaryl, or heterocycle optionally substituted with 
OH or halide; 
R2 is CH2---CH(OH)-CH2 ; 
R3 is a biomolecule bound to R2 via an amine bound; and 
n>l. 
In other embodiments, n >than 1,000, greater than 10,000 
philicity, structural rigidity, and spacing of biomolecules. 20 or even greater than 100,000. 
Representative dicarboxylic acids include, but are not limited A. Synthesis of the Monomers 
to adipic acid, aldaric acid, aspartic acid, azelaic acid, cam- In one embodiment, the synthesis of diglycidyl esters from 
phoric acid, dimercaptosuccinic acid, fumaric acid, glutamic dicarboxylic acids has been optimized, for example to a typi-
acid, glutaric acid, isophthalic acid, itaconic acid, ketoglu- 25 cal overall yield of91 %. The examples of esters synthesized 
taric acid, maleic acid, malic acid, malonic acid, mesoxalic 
acid, n-acetylglutamic acid, oxalic acid, oxaloacetic acid, 
phthalic acid, phthalic acids, pimelic acid, sebacic acid, 
suberic acid, succinic acid, tataric acid, terephthalic acid, 
30 
traumatic acid, dodecanedioic acid, chaetomellic acids, ceri-
poric acids, 1,2-cyclohexane biacarboxylic acid, 1,4-cyclo-
hexane biacarboxylic acid, substituted dicarboxylic acids, 
and combinations thereof. The R group can also have other 
function groups if necessary. The biomolecules that render 35 
the resultant polymer bioactive can be any biologically 
important molecules that have a primary amine group (NH2 ). 
Examples include amino acid, amino acid derivatives, pep-
tides, amine-containing carbohydrates, neurotransmitters, 
40 
and alkaloids. Polymers synthesized using this platform can 
have a wide range of properties/functions because of the wide 
range of monomers. This enables the biomaterials to be tai-
lored for a specific application. 
One embodiment provides a polymer according to the fol- 45 
lowing formula: 
are listed in Scheme 1. 
Scheme 1. 
High yield synthesis of diglycidyl esters 
from dicarboxylic acids. 
0 0 
HO~OH 
sebacic acid 
0 0 
~o~o~ 
~xooH 
°"Cl DCM, reflux 
0 0 
\l"o~o~ 
0 0 
50 A large number of dicarboxylic acid can be used to make the diglycidyl 
esters using the above synthesis method. We have applied this strategy to 
the following acids to illustrate the wide range of possibilities: 
wherein R1 is any alkyl, cycloalkyl, heterocycloalkyl, aryl, 55 
heteroaryl, or heterocycle optionally substituted with halide, 
alcohol, ether, thioether, tertiary amine, ketone, ester, and 
amide. 
R2 is any alkyl, cycloalkyl, aryl, heteroaryl, optionally sub- 60 
stituted with halide, alcohol, ether, thioether, tertiary amine, 
ketone, ester, and amide; 
R3 is a biomolecule bound to R2 via an amine bound; and 
n is ~1. 
In other embodiments, n>than 1,000, greater than 10,000 
or even greater than 100, 000. 
65 
succinic acid 
1,2-cyclohexane biacarboxylic acid 
1,4-cyclohexane biacarboxylic acid 
teraphthalic acid 
HOOC, /'-.... 
-.......,,.-- "cooH Q-COOH 
COOR 
HOOC~COOH 
HOOC~COOH 
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Compounds used to polymerize biomolecules can be 
modified to have a functional group on either end of the 
molecule. Epoxide functional groups are illustrated in the 
diglycidyl esters above, but it will be appreciated that other 
functional groups can be used provided the functional groups 
react with a biomolecule, for example with a primary amine to 
form a polymer. For example, other functional groups include 
but are not limited to carbonyl containing groups, aldehydes, 
carboxylic acids, esters, acid-chlorides, alkyl halides, etc. 
B. Neurotransmitter-Based Biomaterials for Nerve Regen-
eration 
1. Biomimetic Polymers Incorporating Dopamine 
Biomaterials are widely used in disease treatment and 
improving human well-being. Recently, significant advances 
have been made to impart biological activity to biomaterials. 
Most of the existing bioactive materials are derived from 
extracellular matrix (ECM) or are modified with ECM motifs. 
The most widely used ECM motifs include protein epitopes 
such as Arg-Gyl-Asp (RGD), Tyr-Ile-Gly-Ser-Arg (YIGSR) 
(SEQ ID N0:2), and Ile-Lys-Val-Ala-Val (IKVAV) (SEQ ID 
NO: 1 ); and glycosaminoglycans such as heparin. In addition 
to cell-ECM interactions, cell differentiation and survival 
also depend on constant interactions with other cells through 
a plethora of messenger molecules. In one embodiment, the 
biomaterial design strategy uses chemical messengers as 
monomers to impart bioactivities to the resultant biodegrad-
able polymers. To demonstrate the potential of this approach, 
8 
rotransmitters during embryonic development results in 
developmental defects of the brain, suggesting that neu-
rotransmitters play crucial roles as morphogens or neu-
rotrophic factors. Dopamine in particular is vital in axon 
growth and synapse formation during the embryonic stage. A 
biocompatible material containing neurotransmitter func-
tional groups should promote axon growth. Specific design 
parameters address the following criteria: (1) degradability, a 
10 degradable material is advantageous because prolonged pres-
ence of an implant may compress or hinder regenerating 
nerves; (2) degradable functional groups, for example esters 
for their versatile synthesis; (3) dopamine functional groups 
15 to be polymerized, for example, the primary amine because 
the catechol is preserved among the catecholamine neu-
rotransmitters whereas the amine group can be alkylated as in 
epinephrine; ( 4) polymerization mechanism, for example 
between dopamine and an epoxide because it alkylates the 
20 
amines under mild conditions. A representative polymer is 
synthesized from 1,2-cyclohexyldiglycidyl ester and dopam-
ine, hence the abbreviation-PCD (Scheme 2). The polymer 
backbone has biodegradable ester bonds and carries positive 
25 charges, known to increase cell adhesion. The diglycidyl ester 
can be synthesized from virtually any dicarboxylic acid 
allowing control of the property of the polymer backbone. 
The concentration of neurotransmitter functional groups in 
30 the polymer can be adjusted by copolymerization with a 
spacer allowing further control of the structure and function a material based on the neurotransmitter dopamine was pro-
duced. The resultant biomaterial promotes neurite growth 
more vigorously than laminin, poly(D-lysine) (PDL), and a 
tyrosine-based polymer. Other bioactive agents that can be 
polymerized include glutamate, aspartate, histamine, norepi- 35 
nephrine, serotonin, taurine, glycine and 4-aminobutyrate, 
and neuropeptides such as methionine enkephalin. 
of the biomaterials. 
2. Biomimetic Polymers IncorporatingAcetylcholine-Like 
Moieties 
Acetylcholine is a chemical messenger widely studied for 
its role in synaptic transmission of an action potential and is 
known to regulate neuronal cytoarchitecture in embryonic 
and adult neurons. The activation of acetylcholine receptors 
induces neurite outgrowth and may promote the formation 
and strengthening of synapses. Acetylcholine-mediated 
axonal growth is believed to occur via an increase in intrac-
ellular calcium level, which likely initiates intracellular sig-
In addition to repair nerve injury, these biomaterials can 
also be used to differentiate embryonic or adult stem cells. In 
40 
one embodiment, the biomaterials can promote differentia-
tion of embryonic or adult stem cells into neurons because 
many neurotransmitters are expressed at high concentrations 
in the embryonic development of nervous tissues. These 
could serve as a valuable cell source for treatment of neuro- 45 naling events. This is supported by the observation that stimu-
degenerative diseases. Furthermore, multiple types of neu- lating acetylcholine receptors triggers the influx of 
rotransmitters can be integrated in a single material, as neu-
rons are known to express receptors for multiple 
neurotransmitters. Thus, one embodiment provides a poly-
meric biomaterial having at least two different bioactive fac-
tors that have a primary amine as a monomer. For example, 
the biodegradable polymer can include at least two bioactive 
factors selected from the group consisting of dopamine, 
glutamate, aspartate, histamine, norepinephrine, serotonin, 
taurine, glycines, 4-aminobutyrate, and methionine enkepha-
lin. 
For all these materials, the density of the bioactive factor 
can be controlled by copolymerizing with an inert amine such 
extracellular calcium and activates specific gene transcrip-
tion. One of the activated genes is actin, which plays a key role 
in axon extension. Additionally, acetylcholine administration 
50 
affects the direction of neurite growth. Local application of 
the neurotransmitter induces the nerve growth cone to tum 
toward the acetylcholine gradient and the spontaneous 
release of acetylcholine from embryonic neurons suggests its 
55 potential role in pathfinding during synapse formation. 
Because of its roles in regulating neuronal development, 
affecting neurite growth, and guiding the nerve growth cone, 
acetylcholine may be used to elicit and direct nerve regenera-
tion after injury. 
as n-butylamine, leucine ethyl ester, and other simple amines, 60 
simple amino acids, or simple aminocarbohydrates such as 
glucosamine. The synthesis of one such copolymer is illus-
trated in FIG. 1. 
One embodiment provides a polymer produced using 
2-aminoethy 1 acetate with diglycidy 1 sebacate (see Scheme 1, 
resultant polymer abbreviated as PSA). Another embodiment 
provides a polymer synthesized using l,2-cyclohexyldigly-
Neurotransmitters, messengers in neural communication, 
are essential in neuronal outgrowth during embryonic and 
neonatal development and after injury. The depletion of neu-
65 cidyl ester (resultant polymer abbreviated as PCA). The poly-
mers can be used to promote neurite growth, nerve regenera-
tion, and in the treatment of neurological disorders. 
US 8,529,928 B2 
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C. Nucleic Acid Delivery Vehicles 
DNA and RNA are potential therapeutic agents that may 
transform human disease treatment. Unprotected nucleic 
acids are rapidly degraded in the body. Thus a delivery strat-
egy is required to prolong the half-life of therapeutic nucleic 
acids. Viral vectors have great delivery efficiency, but safety 
concerns may limit their clinical utility. While properly 
designed nonviral vectors are safe, they typically have low 
10 
vectors such as PEI, PAGE is likely less toxicity. The relative 
ratio of arginine and Tat epitope in the polymer can be 
adjusted to achieve optimal transfection efficiency. 
Another embodiment provides arginine based polymers 
PSR and PCR synthesized using diglycidyl succinate (see 
Scheme 3) and 1,2-cyclohexyldiglycidyl ester respectively. 
The polymers can form complexes with nucleic acids includ-
ing, but not limited to, plasmid DNA and SiRNA. 
Scheme 3: Production of Arginine Based Polymer PSR 
0 
HO~OH 
0 
]~OH 110° c. H2S04 
D. Cardiovascular Tissue Engineering 
Coronary artery disease is the leading cause of mortality 
and disability in the US and other industrialized countries. 
Current vascular grafts have limited success, especially for 
small arteries like the coronary arteries. Tissue engineering 
may produce small arteries that are mechanically compliant, 
vasoresponsive, and antithrombogenic (resist blood clot for-
mation). Tissue engineered small arteries can already match 
transfection efficiency. Arginine plays a key role in nucleic 
acid condensation and cellular uptake, two essential steps in 
the delivery of genetic materials. DNA binding proteins, his-
tones and protamines, use arginine and lysine to bind DNA. 60 
Furthermore, an 11 amino acid epitope (YGRKKRRQRRR) 
(SEQ ID N0:3) of HIV Tat protein, known to transport exog-
enous molecules across cell membranes, contains 6 arginines. 
One embodiment provides an arginine-based PAGE inte-
grated with Tat epitope having improved the transfection 
efficiency of nucleic acids. Compared with non-degradable 
65 the strength of native vessels, but antithrombogenicity 
remains elusive. Endothelial cells (ECs) cover the lumen of a 
blood vessel to provide antithrombogenicity in healthy vas-
US 8,529,928 B2 
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culature. Selective binding to ECs is critical to ensure anti-
thrombogenicity as adhesion of other blood cells such leuko-
cytes and platelets promotes thrombosis. A plasma 
fibronectin epitope is known to selectively bind EC even at 
low surface density (10 pmol/cm2 ) 
12 
Another embodiment provides biomimetic polymers 
incorporating YIGSR (SEQ ID N0:2) or IKVAV (SEQ ID 
NO:l) as the biomolecules. It will be appreciated that more 
than one type of biomolecules can be incorporated in to a 
polymer. Additionally, the biomolecules can be selected 
~ oyo'-/ 
~Ntf'YOH 
HO~ x ~) 
OH 
0 ) 0 
0 0 
~o 
0 0 
P(TF-co-GREDV) 
GREDV (SEQ ID N0:4 ), wherein the amino end of glycine depending on the tissue to be treated. For example, neuronal 
will be polymerized was used. GREDV (SEQ ID N0:4) was 25 biomolecules can be incorporated into polymers for treating 
polymerized with diglycidyl terephthalate. The resultant 
polymer, P(TF-co-GREDV 100), was characterized using 
FTNMR and FTIR (FIG. 7). The epitope has been copoly-
nervous tissue. 
E. Matrices and Growth Factors 
1. Matrix Materials 
merized with 'inert' amino compounds including but not lim- 30 
ited to glycine ethyl ester and phenylalanine ethyl ester to test 
Growth factors play an important role in regulating the 
body functions in healthy and diseased states. A controlled 
delivery of growth factors can significantly increase the half 
life and thus bioavailability of the growth factors. Many 
growth factors are stored in the heparin-bound state and 
the low limit of eptiope concentration for function and high 
limit of eptiope concentration that inhibits cell migration. The 
structure of one such polymers, P(TF-co-GREDV), a copoly-
mer of phenylalanine ethyl ester, GREDV (SEQ ID N0:4), 
and diglycidyl terephthalate is illustrated above. Baboon 
endothelial progenitor cells (BaEPCs) displayed normal mor-
phology and phenotypic expression of von Wille brand factors 
(vWF) and proliferated well on P(TF90-co-GREDV10) (FIG. 
8). BaEPC adhesion weakened in the presence of 40 fmol/ml 
GREDV (SEQ ID N0:4) dissolved in medium indicating that 
GREDV (SEQ ID N0:4) is the functional group that pro-
moted EC adhesion. 
The adhesion strength between P(TG90-co-GREDV10) 
[glycine ethyl ester as the spacer (90%), GREDV (SEQ ID 
N0:4) (10%) terephthalate backbone] and endothelial cells 
under arterial sheer stress was quantitatively evaluated. To 
save the consumption of baboon EPCs, human umbilical vein 
endothelial cells (HUVECs) were used as a model of EPCs. 
HUVECs adhere to the polymer surfaces well and arterial 
shear stress resulted in minimal cell detachment. The polymer 
surfaces were conditioned in Ml 99 media overnight and 
washed with DPBS before plating HUVECs. Cells were 
allowed to adhere for four hours before starting shear condi-
tions in a parallel plate flow chamber. Microscopy of the cells 
indicated that they remained attached to the surface after 1 
hour of 40 dynes/cm2 laminar shear stress. 
Thus, the disclosed biomimetic polymers can be used to 
engineer endothelial cells to vascularize tissue or organs. This 
polymer or its analogs can also be used to coat any surfaces 
that needs to be endothelialized such as stents and other blood 
contacting surfaces. This polymer itself can be used to form 
devices that contacts bloods. 
35 released when the body needs them. Heparin is heavily nega-
tively charged. One embodiment provides poly-cations con-
jugated to [heparin:growth factor] complexes as a way to 
control the release of the growth factors. 
Matrices using the disclosed biomimetic polymers can be 
40 formed by crosslinking ionically, covalently or by combina-
tions thereof, one or more polymeric materials to form a 
polymeric matrix. Alternatively the matrices can be formed 
by entangling polymeric fibers. In certain embodiments the 
matrices are formed having sufficient inter-polymer spacing 
45 to allow for ingrowth or migration of cells into the matrix. 
One embodiment provides a matrix formed by one or more 
of the disclosed biomimetic polymers. In certain other 
embodiments, the matrix is formed by one or more of the 
50 
disclosed biomimetic polymers and a second polymer. The 
second polymer can be natural or synthetic. Suitable natural 
polymers include, but are not limited to proteins and polysac-
charides. The most preferred protein is fibrin, although other 
proteins such as collagen and gelatin can also be used. 
55 Polysaccharides and glycoproteins may also be used. In some 
embodiments, it is also possible to use synthetic polymers 
which are crosslinkable by ionic or covalent binding. 
The matrix material is preferably biodegradable by natu-
rally present enzymes. The rate of degradation can be 
60 manipulated by the degree of crosslinking and the inclusion 
of protease inhibitors in the matrix. 
2. Degradable Linkages 
The polymers forming the matrix can be modified to 
include one or more degradable linkages. When protein poly-
65 mers are included, enzyme cleavage sites can be included, 
such as the site for cleavage by thrombin. These sites may be 
degradable either by non-specific hydrolysis (i.e., an ester 
US 8,529,928 B2 
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bond) or they may be substrates for specific enzymatic (either 
proteolytic or polysaccharide degrading) degradation. These 
degradable sites allow the engineering of more specific 
release of bioactive factor from the matrices. For example, 
degradation based on enzymatic activity allows for the 
release of bioactive factors to be controlled by a cellular 
process rather than by diffusion of the factor through the 
matrix. 
14 
The degradation sites allow the bioactive factor to be 
10 
released with little or no modification to the polymer, which 
ily, and vascular epithelial growth factor ("VEG"), VEG-F, 
among others. In general, growth factors which are consid-
ered to bind heparin will elute from a heparin-affinity column 
at NaCl concentrations above physiological levels (greater 
than or equal to 140 mM). Additional"heparin-binding" 
growth factors include interleukin-8, neurotrophin-6, hep-
arin-binding epidermal growth factor, hepatocyte growth fac-
tor, connective tissue growth factor, nerve growth factor, pla-
cental growth factor, platelet derived growth factor, insulin 
like growth factor- I, platelet derived growth factor-BB, inter-
feron-gamma, midkine, hepatocyte growth factor, connective 
tissue growth factor, and heparin-binding growth associated 
may result inhigher activity of the factor. In addition, it allows 
the release of the factor to be controlled by cell specific 
processes, such as localized proteolysis, rather than diffusion 
from some porous materials. This allows factors to be 15 molecule. These growth factors have been shown to regulate 
tissue maintenance, growth, and repair. released at different rates within the same material depending 
Heparin-binding domains naturally occur in many differ-
ent families of growth factors. One of these families with one 
20 or more member that bind heparin are the fibroblast growth 
factors (Presta, M., et al. (1992). Biochemical and Biophysi-
cal Research Communications. 185:1098-1107). Additional 
growth factors which bind heparin include transforming 
on the location of cells within the material. Cell specific 
proteolytic activity is vital in applications such as nerve 
regeneration, which occur over long periods of time. This also 
reduces the amount of total growth factor needed, since its 
release is controlled by cellular processes. Conservation of 
growth factor and its bioavailability are distinct advantages of 
exploiting cell specific proteolytic activity over the use of 
diffusion controlled release devices which characteristically 25 
result in the loss of a significant amount ofbioactive factor in 
growth factor, bone morphogenetic factor, interleukin-8, neu-
rotrophin-6, vascular endothelial cell growth factor, heparin-
binding epidermal growth factor, basic fibroblast growth fac-
tor, hepatocyte growth factor, connective tissue growth factor, 
midkine, and heparin-binding growth associated molecule 
an initial burst release. 
Enzymes that could be used for degradation are numerous. 
Proteolytically degradable sites could include substrates for 30 (Gatz, R., et al., (1994), Nature. 372:266-269; Kaneda, N. et 
al., (1996) J. Biochem. 119:1150-1156; Kiguchi, K., et al., 
(1998) Mo!. Carcinogensis. 22:73-83; Kinosaki, M., et al., 
(1998). Biochim. Biophys. Acta. 1384:93-102; McCaffrey, 
collagenase, plasmin, elastase, stromelysin, or plasminogen 
activators. 
3. Heparin; Heparin Binding Peptides 
T., et al., (1992) J. Cell. Physiol. 152:430-440; No lo, R., et al., 
(1996) Eur. J. Neurosci 8:1658-1665; Spillmarm, D., et al., 
(1998). Journal of Biological Chemistry. 273:15487-15493; 
Steffen, C., et al. (1998); Growth Factors. 15:199-213. 
Tessler, S., et al, (1994) J. Biol. Chem. 269:12456-12461). 
The matrix can be modified through the inclusion of hep-
arin and/or heparin binding fragments, which bind directly or 35 
indirectly to proteins which bind to heparin. In the latter case, 
the peptide can bind to heparin, which is then available for 
binding to factors which include a heparin binding site, or the 
peptide can itself contain a heparin portion which is bound by 
certain heparin-binding growth factors. These can be attached 
40 These factors have shown the potential to enhance healing in 
to the matrix material using standard techniques, as discussed 
in more detail below. 
In a preferred embodiment, heparin is incorporated in to 
the cationic polymer and the [polymer:heparin] matrix is 
formed. In another embodiment, heparin is attached to the 
polymeric matrices non-covalently using a two-part system 
consisting of a peptide chimera and heparin itself. The pep-
tide chimera consists of two domains, a factor XIIIa substrate 
and binding domain specific for the polymer, in particular the 
biomolecules incorporated into the polymer. Once the pep-
tide chimera is cross-linked into the polymeric matrix it 
attaches the heparin (or other polysaccharides) by non-cova-
lent interactions. 
4. Bioactive Factors 
Many growth factors that are involved in morphogenesis, 
both in the developing organism and in the adult, bind to 
extracellular matrix molecules. This affinity provides for a 
local mode of action of the morphogen, preventing uncon-
trolled distal influences. The principal matrix affinity interac-
tion that is involved in this localization of influence is for 
heparin and heparan-sulfate proteoglycans. Growth factors 
that bind to heparin include the transforming growth factor 
("TGF")-beta superfamily (including the bone morphogenic 
proteins, "BMPs"), the fibroblast growth factor ("FGF") fam-
many different types of tissue including vasculature, skin, 
nerve and liver. Therefore, these materials can be used with 
the disclosed polymers and polymer matrices to enhance 
45 wound healing in many different parts of the body by select-
50 
ing the appropriate growth factor and appropriate biomimetic 
polymer. 
5. Incorporation ofBiofactors into the Matrices 
A simple way to incorporate many bioactive factors of 
interest in healing and regeneration into the polymer matrices 
is to include heparin and use the heparin to sequester heparin-
binding proteins, such as heparin-binding growth factors. 
55 This can be accomplished by forming a nanometer to 
micrometer scale fibrillar to bead-like matrix that precipitate 
out of an aqueous medium by charge neutralization between 
the cationic polymer in and the anionic heparin so that the 
heparin and the polymer fibers entangle; indirectly by cross-
60 linking a heparin-binding peptide into the polymer matrix and 
binding heparin to this peptide non-covalently (using a bi-
functional peptide containing a heparin-binding domain and 
polymer binding domain); directly coupling a heparin-pep-
65 tide chimera (where the heparin is chemically attached to a 
peptide containing a binding site for the polymer). Regardless 
of the method of incorporation, the incorporated heparin can 
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then sequester proteins, such as growth factors with heparin 
binding affinity, in the polymer matrix in a manner similar to 
the way that they are sequestered to the extracellular matrix in 
nature. Heparin can also protect these factors from proteolytic 
degradation and prolong their activity until they are released 
from the matrix. Heparin can also present the growth factors 
in their bioactive form, thus greatly increase the efficiency of 
the therapy. 
III. Methods of Use 
16 
EXAMPLES 
Example 1 
Synthesis and Characterization ofBiomimetic 
Polymers 
Diglycidyl 1,2-cyclohexanedicarboxylate and dopamine 
were dissolved in N,N-dimethylformamide (DMF) with an 
10 optional 0.1 % Mg(Cl04 ) 2 under N2 with constant stirring. 
The disclosed compositions can be used in tissue engineer-
ing, wound healing, drug delivery, nucleic acid delivery, and 15 
The reaction mixture was heated at 90° C. for 7 days and the 
resultant viscous liquid was precipitated in ethyl ether. The 
precipitate was subjected to a quick washed with D.I. water to 
remove the catalyst and byproducts. The purified PCD (71 % 
yield) was lyophilized and stored under N2 at -40° C. The 
polymer was soluble in DMF, low molecular weight alcohols 
and ketones but was insoluble in water. PCD, 1 H NMR nerve regeneration. In certain aspects, the compositions are 
combined with a drug, for example a nucleic acid, and are 
administered to host, for example a mammal. The composi-
tions either alone or in combination with a second therapeutic 20 
can be used to treat various pathologies, including but not 
(methanol-d4 ) ll 6.62-6.55 (br, 3H), 4.18-3.80 (br, 3H), 3.60-
3.31 (br, 3H), 3.16-2.98 (br, 2H), 2.90-2.40 (br, 6H), 2.02-
1.80 (br, 2H), 1.78-1.61 (br, 2H), 1.49-1.17 (br, 6H). FTIR: 
1727 cm- 1 (ester C=O), 1451 cm- 1 (C-N), 1289 cm- 1 
(catechol C-0), 814 and 866 cm- 1 (1,2,4-trisubstituted aro-limited to cancer, diabetes, inflammation, genetic disorders, 
age-related disorders, nerve degeneration, bone fractures, 
wounds, and tissue regeneration, Nucleic acids include, but 
are not limited to RNA, DNA, and combinations thereof. 
Anti sense RNA, antisense DNA, micro RNA, siRNA, nucleic 
acids encoding a peptide or inhibitory nucleic acid can be 
delivered to a cell or host using the disclosed compositions. 
matic ring). The absence of absorption at 1674 cm-1, 1662 
cm-1, and 1564 cm- 1 that are associated with dopamine-
25 quinone, indicating minimal oxidation of catechol to quinine 
(FIG. 2A). The molecular weight of PCD was found to be 
5,260 as determined by MALDI-MS. When tyrosine ethyl 
ester was used in lieu of dopamine, PCY was obtained at 92% 
yield. PCY, 1H NMR (methanol-d4 ) ll 7.09-6.73 (br, 2H), 
In one embodiment, the disclosed composition is admin- 30 
istered to a host at an injury site to promote tissue growth or 
6.68-6.41 (br, 2H), 4.12-3.61 (br, 7H), 3.58-3.30 (br, 3H), 
3.16-2.62 (br, 6H), 2.59-2.37 (br, 2H), 2.08-1.77 (br, 3H), 
1.75-1.60 (br, 2H), 1.45-1.14 (br, SH). FTIR: 1732 cm- 1 
(ester C=O), 1220 cm- 1 (phenol C-0), 1377 cm- 1 (phenol 
0-H in-plane bending), 834 cm- 1 (para-substituted aro-
regeneration. For example, the disclosed compositions can be 
applied to areas of trauma in the central or peripheral nervous 
systems or the circulatory system. The compositions can pro-
vide a surface or three dimensional scaffold to assist cellular 
growth in the areas of trauma. In certain embodiments, neural 
cell or cardiac cell growth is induced relative to controls. 
35 matic ring) (FIG. 2B). PCA, PCR, PSA, and PSR were 
obtained using similar synthetic methods with the respective 
monomers. P(TF-co-GREDV) was synthesized similarly 
except the reaction temperature was 60° C. 
Scheme 2. PCD was synthesized using dopamine as a monomer. 
This synthesis strategy can be applied to a large number of diglycidyl esters and biomolecules 
containing primary amines. The key difference between PCD and PCY is the -OH group of the catechol. 
DMF,N2 
90° C., 7 d 
PCD 
:i:Yo 
HO O\ 
Replaced by -- OH 
HinPCY 
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The addition of equimolar amount of dopamine to digly-
cidyl 1,2-cyclohexanedicarboxylate in N,N-dimethylforma-
mide (DMF) yielded PCD as a pale yellow powder that 
melted at 130-135° C. without noticeable degradation. 
Nuclear magnetic resonance (NMR) spectra revealed a 5 
change of chemical shift from approximately 3.2 ppm in the 
diglycidyl ester to 4.0 ppm in PCD, consistent with the open-
ing of the epoxide ring. The intense C=O stretch at 1730 
cm- 1 in Fourier-transformed infrared (FTIR) spectra con-
firmed the formation of the ester bonds, while the band at 866 10 
and 814 cm- 1 revealed the presence of the catechol units in the 
polymer (FIG. 2). The absence of absorption at 1674 cm- 1 , 
1662 cm-1, and 1564 cm- 1 indicated that oxidation of cat-
echol to quinone was undetectable in PCD. For PCY, the 15 
presence of phenol was confirmed by a medium-intensity 
absorption at 834 cm- 1 (FIG. 2). Polymerization of dopamine 
converted its primary amine to a tertiary amine, which limited 
the formation of dopaminechrome, the oxidative intermediate 
to dopamine quinone. This increased the oxidative resistance 20 
of the catecholamine, thus minimizing the toxicity associated 
with dopamine quinone. The ester bond in PCD rendered the 
polymer biodegradable, with a half-life in phosphate buffered 
saline solution (PBS) of approximately 50 days at 37° C. 
(FIG. 3A). The ultimate degradation products, which are 25 
under investigation, are most likely to be N,N-bis(2,3-dihy-
droxypropyl)dopamine and 1,2-cyclohexane dicarboxylic 
acid. 
18 
cells was measured in each group at any given time point. The 
number of metabolically active cells was monitored by the 
MTT assay. 
PCD's capability at promoting neurite outgrowth in vitro 
was evaluated using rat pheochromocytoma (PC 12) cells that 
have been widely used in studying neuronal communication 
and interaction between biomaterials and neurons. The cells 
were primed with NGF for 24 h instead of 9 days to better 
differentiate the materials' intrinsic ability of promoting neu-
rite growth. To verify whether the catecholamine functional 
groups were recognized by the cells, a control material (PCY) 
based on tyrosine, the precursor of dopamine was synthe-
sized. Cell proliferation, differentiation and morphology 
were also compared with PDL and laminin, the standard 
substrates for culturing many types of neurons. 
The in vitro biocompatibility of PCD was evaluated by 
monitoring the number of adhered metabolically active cells 
using 3-( 4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay as previously described. PCD appeared 
to be at least as biocompatible as standard neuron-culturing 
materials in vitro. The cell adhesion and proliferation on PCD 
resembled those of PDL (FIG. 3B). Cells reached confluence 
and started to detach from the surfaces after 7 days. PC12 
cells with neurites longer than 20 µmare generally considered 
differentiated nerve cells. The differentiation level reached as 
high as 84±12% on PCD at day 5 (FIG. 3C). In comparison, 
the highest level of differentiation was 30± 10%, 33± 13% and 
16±7.7% on PCY, PDL, and laminin respectively. PCD 
induced significantly more cell differentiation as culture time 
Example 2 
Biocompatibility of PCD 
30 increased (ANOVA, P<0.05). In contrast, the percentage of 
differentiated cells on the controls remained in the 15-35% 
range and did not change significantly throughout the entire 
culture period. 
In vitro degradation, biocompatibility and nerve differen-
35 
tiation: PC D powders (10 mg) were compressed into 5 mm 
diameter, 0.5 mm thick pellets ona Carver press at 9000 lb for 
2 min under N2 , and submerged into 15 ml sterile PBS solu-
tion in a centrifuge tube at 37° C. The disks were retrieved at 
pre-determined time point, dried in a vacuum oven at 50° C. 40 
and 100 mTorr overnight, and weighed. 
PCD solution was filtered through a 0.2 µm filter and added 
to a 24 well-plate (100 µI/well), dried under vacuum for 3 
days and washed with PBS. The plates were soaked in serum-
free RPMI medium overnight. PCY, PDL, and laminin- 45 
coated plates subjected to the same washing and soaking 
treatment were used as controls. 
The differentiated cells on all four materials exhibited neu-
ron morphology. However, the median neurite length on PCD 
was significantly higher than that on the controls. Moreover, 
the difference between PCD and the control increased with 
time (FIG. 3D). At day 7, the neurites were approximately 
150% longer than those on PCY, which yielded the longest 
neurites in the control group. The increase of median neurite 
length with time was significant on PCD, whereas the differ-
ence of neurite length on all control surfaces was statistically 
insignificant over the culture period. 
The distribution of neurite length showed distinct patterns 
on PCD that were absent in the controls (FIGS. 3E, F). The 
neurite length was divided into 10 µm increment up to 100 µm 
and larger increments as appropriate above 100 µm. The 
percentage of neurite lengths within a defined range was 
plotted (for example, the data point at 50 µm represents the 
percentage of neurite length from 40 to 50 µm). Distinct peaks 
were visible on the PCD curves. As culture time increased, the 
fraction of longer neurites increased considerably, shifting 
the curve further to the right. The percentage of neurites more 
than 20-µm-long increased sharply at day 3, and reached as 
PC12 cells were cultured in 85% RPMI 1640, 10% heat-
inactivated horse serum (HHS) and 5% fetal bovine serum 
(FBS), and maintained in a humid, 5% C02 incubator at 37° 50 
C. PC! 2 cells were primed for 24 h in differentiation medium 
(RPMI 1640, 1 % HHS and 0.5% FBS, 50 ng/ml NGF, and 20 
µg/ml gentamycin) prior to seeding at a density ofl xl 04/cm2 . 
The cells were maintained in an incubator with medium 
exchanged every 2 days. 
Cell morphology, neurite length measurements, and MTT 
assay: Cell morphology was monitored using an inverted 
phase contrast microscope at 200x. Neurite length, defined as 
the distance from the tip of the neurite to the junction between 
the cell body and neurite base, was measured on day 1, 3, 5, 60 
and 7. In the case of branched neurites, the length of the 
longest branch was used. For each well, 5-6 images were 
randomly acquired to ensure >500 cells were captured. Dif-
ferentiation level was quantified by the percentage of differ-
entiated cells with neurite longer than 20 µm. The average 65 
neurite length was calculated by dividing the total neurite 
length by the numberof the cells with neurites. More than 500 
55 high as 77% on day 7. At day 5, approximately 20% of the 
neurites were longer than 50 µm, and the percentage nearly 
doubled at day 7. In contrast, less than 30% of the neurites 
were longer than 20 µm on the control materials throughout 
the culture period, and their neurite distribution curves 
showed fewer and less distinguishable peaks. A possible 
explanation for this difference is that differentiated PC12 
cells developed distinct axons and dendrites on PCD, whereas 
the control materials did not induce neuronal differentiation 
sufficiently to reach such a stage. 
The number of cells exhibiting typical neuron morphology 
was significantly higher on PCD than on the controls Neurites 
up to 180-µm-long began to appear on PCD 3 days after 
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seeding, and grew up to 250 µm after 5 days of culture. In 
comparison, the longest neurites reached approximately 80 
µm, 100 µm, and 60 µm on PCY, PDL, and laminin respec-
tively. The nerve growth cone is a highly motile structure at 
the tip of an extending axon that explores the extracellular 
environment and guides the extension of the axon. The pri-
mary morphological characteristic of a growth cone in vitro is 
a sheet-like lamellipodium with numerous fine processes 
called filopodia. The cells on PCD displayed structures 
resembling growth cones at the end of their neurites. Growth 10 
cone-like structures were also observed on control surfaces. A 
number of cells on PCD exhibited extensive filopodia along 
their neurites in a similar fashion to the spines on spiny 
neurons. In contrast, the filopodia density was lower for the 
neurites on PCY. Low dopamine level has been shown to 15 
cause a reduction of dendritic spine density in dopaminocep-
tive neurons. The higher filopodia density on PCD indicated 
that the catecholamine functional groups could induce unique 
responses in differentiated PC12 cells. 
20 
Example 3 
In Vivo Biocompatibility of PCD 
20 
a more permissive environment for regenerating axons, and 
multi-month degradation time of the material would be ben-
eficial for nerve regeneration, which usually requires several 
months. 
Example 4 
Characterization of PCA 
Two polymers containing acetylcholine functional groups 
were synthesized using 2-aminoethyl acetate with diglycidyl 
sebacate (see Scheme 1, resultant polymer abbreviated as 
PSA) and 1,2-cyclohexyldiglycidyl ester (resultant polymer 
abbreviated as PCA). PCA displayed a neuroinductive effect 
on differentiated PC 12 cells and primary rat DRG neurons. 
The cell growth rate matched that of PDL (FIG. 4). Long 
neurites up to 100 µm appeared at day 1. The neurite length 
and cell differentiation rate resembled that of PCD. 
Example 5 
Arginine Containing Polymer Synthesis and 
Characterization 
Succinic acid was purchased from TCI. Arginine ethyl 
ester dihydrochloride was purchased from Research Organ-
ics. 1,3 meta chloro peroxy benzoic acid was purchased from 
Acros. All other chemical were purchased from Alfa Aesar 
and used without purification. Flash chromatography was 
In vivo biocompatibility: PCD pellets (20 mg, 5 mm diam- 25 
eter, 1 mm thick) were sterilized by plasma for 40 min. The 
implants were soaked in sterile PBS containing 0.1 w/v % 
ascorbic acid on an orbital shaker for 2 h prior to implantation. 
Male Sprague Dawley rats weighing 300-350 g were 
implanted with PCD under anesthesia maintained by hal-
othane inhalation. Under sterile conditions, a gluteal muscle 
splitting technique was used to expose both sciatic nerves. 
Eight animals received two sterile implants with one implant 
placed directly underneath each sciatic nerve on the underly-
ing muscle bed. Control animals (n=4) underwent either 
sham surgery, with exposure of both sciatic nerves followed 
30 done on a Buchi Fraction Collector C-660 w/UV photometer 
C-635. Nuclear magnetic resonance (NMR) spectra were 
recorded on a 400 MHz Mercury-400BB NMR. FTIR spectra 
were recorded on a ThermoNicolet IR-100 spectrometer. 
Dynamic light scattering measurements were recorded on a 
by closure (n=3 ), or no surgery (n= 1 ). The muscle layer was 
closed with vicryl sutures and the skin was closed with 
staples. Animals were cared for in compliance with protocols 
approved by the Committee on Animal Care of the Georgia 
Institute ofTechnology following NIH guidelines for the care 
and use of laboratory animals (NIH publication No. 85-23 
rev. 1985). 
35 Zeta Potential/Particle Sizer NICOMP 380 ZLS. Aqueous 
phase gel permeation chromatography was performed on a 
Waters 2690 Separation Module with the 2410 UVNis and 
2487 RI units using a 60 A YMC-PackAqueous GPC colunm. 
The molecular weight and polydispersity of the polymer are 
40 reported relative to polyethylene glycol standards. 
Explants were harvested at 7, 14, 28, 60 days post-implan-
tation. The surgical wounds were re-opened; the gluteal mus- 45 
culature was removed en bloc with the sciatic nerve and the 
polymer renmant, and fixed in 10% formalin for 3 days prior 
to histological analysis. The control tissues were similarly 
harvested and fixed at the same time points. The tissues were 
serially dehydrated in a graded series of ethanol and xylenes 50 
washes and embedded in paraffin. Ten micron thick sections 
were cut along the longitudinal axis of each implant. Sections 
were stained using a standard protocol for haematoxylin and 
eosin (H&E), and Mason's trichrome stain (MTS). The his-
tological samples were analyzed blindly and independently 55 
by a histopathologist. Sections were analyzed for degree of 
inflammation and fibrosis. The inflammatory response to 
each implant was assessed by rating the levels oflymphocytic 
and histiocytic infiltrate; and fibrosis was identified by col-
lagen deposition. 60 
Preliminary in vivo biocompatibility studies indicated that 
PCD did not cause nerve degeneration or fibrous encapsula-
tion when implanted immediately adjacent to rat sciatic 
nerves. The brown renmants of the 20 mg-implants were 
well-circumscribed with a cavitated center containing 65 
inflammatory infiltrates including phagocytic cells up to 8 
weeks postimplantation. The absence of fibrosis would yield 
acetylcholine 
acetylcholine-mimetic 
fraction of the polymer 
Monomer synthesis included preparing diallyl succinate 
by adding 8:1 molar amounts of ally! alcohol and succinic 
acid respectively, then adding concentrated sulfuric acid 
(0.1 % volume of ally! alcohol) drop-wise to the solution. The 
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reaction mixture was stirred and refluxed at 105° C. over-
night. Sodium bicarbonate was added to the reaction to neu-
tralize the sulfuric acid and the reaction mixture was 
rotovaped at 60° C. for 30 min followed by ethyl acetate/ 
water extractions. Water in the organic phase was then 5 
removed by brine and anhydrous sodium sulfate overnight. 
The product can be stored at room temperature. 1 H NMR 
(CDCl3 -d1): 5.87 (m, 2H), 5.23 (m, 4H), 4.57 (d, 4H), 2.65 (s, 
4H). 
Diglycidyl succinate synthesis included 3:1 molar 10 
amounts of 1,3 meta chloro peroxy benzoic acid (mCPBA) 
and diallyl succinate respectively dissolved in dichlo-
romethane (DCM). The reaction was stirred and refluxed at 
40° C. for 5-6 h. Reaction mixture was then run through an 
ionic resin column containing tertiary amine beads. The prod- 15 
uct was further purified using low pressure liquid chromatog-
raphy and the final product was stored under N2 at-20° C. 1H 
NMR (CDCl3 -d1): 4.40 (dd, 2H), 3.95 (q, 2H), 3.20 (m, 2H), 
2.84 (t, 2H), 2.68 (s, 4H), 2.63 (q, 2H). 
The arginine-based polymer was synthesized via polycon- 20 
densation reaction of diglycidyl succinate and arginine ethyl 
ester, with 0.1 % molar amount of Mg(Cl04 ) 2 in anhydrous 
N,N-dimethylforamide (DMF) under N2 . The reaction mix-
ture was stirred and kept at 60° C. for 7 days. The resultant 
polymer (PSR, Scheme 3) was placed under vacuum and 25 
heated to 60° C. for 24 h. PSR was thenredissolvedinmetha-
22 
The ability of a polymer to compact DNA through electro-
static interactions between the positively charged nitrogens of 
the polymer and the negatively charged phosphates in the 
DNA backbone is critical to its success in gene delivery. The 
ability of PSR to self-assemble with plasmid DNA was exhib-
ited through an agarose gel retardation assay, particle size 
analysis, and zeta potential measurements. 
Agarose gel electrophoresis separates molecules based on 
charge and size. Complete retardation of the DNA/polymer 
complex is a result of charge neutralization, and is one way to 
measure a polymer's aptitude to complex DNA. Polymer and 
DNA were both placed in solutions of molecular grade water, 
with the concentration of polymer changing to the desired 
NIP ratios. Polyplexes were formed by adding the DNA solu-
tion drop-wise to the polymer solution and then gently vor-
texing for 15 min. The resulting polyplex solution was then 
run on an agarose gel by gel electrophoresis. DNA was com-
pletely retarded at a NIP ratio between 4/1-8/1. From these 
results a NIP ratio ofl 0/1 was used for all further experiments 
to ensure the plasmid was completely compacted. 
Agarose gel retardation assays can be beneficial by estab-
lishing the optimal polymer concentration to completely 
complex DNA, but it can not determine the actual size of the 
polyplexes formed nor the actual charge (zeta potential) car-
ried by these polyplexes. Particle size and zeta-potential can 
be ascertained through dynamic light scattering (DLS) mea-
surements. These measurements resulted in polyplexes that 
averaged 68 nm in diameter and carried a charge of +41 m V. 
Particles under 200 nm in diameter are capable of entering 
no!, washed with ethyl acetate, and placed under vacuum and 
heated at 60° C. overnight. The polymer was characterized by 
FTNMR, FTIR, differential scanning calorimetry, and gel 
permeation chromatography. 30 cells through the endocytotic pathway, so PSR/DNA com-
plexes should not experience difficulty entering the cell.Also, 
the positive charge on the particles could improve interactions 
with negatively charged proteoglycans present on the cell 
surface. 
The polycondensation reaction between arginine ethyl 
ester and diglycidyl succinate yielded a pale yellow powder 
that is soluble in water, low molecular weight alcohols, and 
DMF. NMR spectra revealed the change in chemical shift 
from -3.2 ppm in the diglycidol ester to -4.0 ppm in PSR. 35 
This shift corresponds to the ring opening of the diglycidol 
ester. The intense C=O stretch at 1735 cm- 1 in the FTIR 
spectra confirmed the formation of ester bonds, and the 
intense band at 1673 cm- 1 with a shoulder at 1635 cm- 1 
Example 7 
Particle Sizing ands-Potential Measurements 
DNA/Polymer complexes were formed in the same manner 
as explained in the agarose gel retardation assay. Samples 
were diluted with 900 µL of molecular grade water and aver-
age particle sizes ands-potential measurements were carried 
out at 25° C. Three measurements were made on each sample, 
established the presence of the guanidine side chain associ- 40 
ated with arginine. PSR has a melt temperature of 88.1° C. 
and a glass transition temperature of 42.8° C. according to 
differential scanning calorimetry measurements. The thermal 
properties of PSR indicate it will maintain its physical prop-
erties when exposed to the internal temperature of the body. 45 and the average diameter ands-potential were reported. The 
10:1 PSR:DNAzetapotential was +41mV.3.5:1 PSR:DNA 
zeta potential was +20 m V. The size of particles formed at 
3.5:1 :PSR:DNA was approximately 70 and 130 nm, typically 
about 100 nm. 
Example 6 
Agarose Gel Retardation Assay 
50 
The 4.7 kb plasmid DNA, pEYFP-Nl, contains the 
enhanced yellow fluorescent protein driven by the human 
CMV promoter. Plasmid DNA was amplified by insertion 
into JM-109 E. coli, and was purified using the Maxi-Prep 
DNA Purification kit from Qiagen. The purity of the plasmid 55 
DNA was measured by UVNis (TECAN Satire) withA260/ 
A280 in the range of 1.7-1.85. 
DNA/Polymer complexes were formed by adding 50 µL of 
plasmid DNA solution (0.04 µg/µL) in molecular grade water 
to 50 µL of polymer solution in molecular grade water. Poly- 60 
mer concentrations were altered to yield the desired NIP 
ratios. These mixtures were gently vortexed and allowed to 
incubate at room temperature for 45 minutes. From these 
mixtures, 10 µL was loadedona0.6% agarose gel with a 10% 
Ficoll 400 loading buffer (without bromophenol blue) in a 20 65 
mM HEPES buffer. The gel was run at 108 V for 60 minutes 
and visualized by ethidium bromide staining. 
Example 8 
Cytotoxicity Assay 
Baboon smooth muscle cells (bSMCs) were cultured in 
24-well tissue culture treated polystyrene plates at a seeding 
density of approximately 40,000 cells well in 1 ml ofMCDB 
131 growth medium (10% FBS/1% glutamine). Cells were 
grown overnight up to 70% confluency then growth medium 
was replaced with appropriate amounts of polymer and 
diluted with serum free medium to a total volume of 1 mL. 
This polymer media was filtered with a 0.2 µm before being 
used. Cells were incubated at 37° C., 5% C02 for 4 h, and then 
metabolic activity was measured by MTT assay. Polymer 
medium was replaced with 400 µI growth medium and 100 µI 
MTT solution (5 mg/mL), and incubated at 37° C. for 4 h. 
MTT media was removed, and replaced with 500 µI of lysis 
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buffer (10% w/v sodium dodecyl sulfate in O.OlM HCl) fol-
lowing a D-PBS wash. Cells digest was incubated at room 
temperature for 1-2 hand absorbance of each sample was 
measured on a microplate reader (TECAN SAFIRE) at 560 
nm. 
24 
port material into cells, and these methods can either be 
qualitative or quantitative. Some examples of these tech-
niques include transfecting with a reporter plasmid (lucifer-
ace, eGFP) or fluorescently labeling the nucleic acid. The 
5 fluorescent dye YOY0-1 was used to track the movement of 
plasmid DNA in this series oftransfections. PEI and PLL have both been used extensively in gene 
delivery and are considered two of the more well-known 
non-viral vectors. These vectors are often used as a basis of 
comparison for new cationic polymers in the field of gene 
therapy. PEI is considered successful due to its high transfec-
tion efficiency, and PLL was one of the first cationic vectors 
used and possess a biodegradable composition. Even with 
their advantageous qualities they both have limitations. The 
trade-off for PEI having a high transfection efficiency is its 
adeptness to be cytotoxic to cells. PLL has also been shown to 15 
be cytotoxic by inducing cell apoptosis in a wide variety of 
cell lines. MTT assay was used to measure the toxicity of PSR 
Plasmid DNA was intercalated with YOY0-1. This was 
then complexed with PSR to examine its capacity to deliver 
nucleic acids across the cell membrane. The polyplexes were 
10 
observed inside of the cells 4-5 hours aftertransfection, simi-
lar to the positive control, linear PEI (25 kD) at a NIP ratio of 
7 /1. The polyplexes appeared to be contained within endo-
somes, as indicated by the punctated fluorescent signals. 
These data demonstrated that PSR can transport genetic 
information into cells. 
PCR at unoptimized concentration exhibited higher trans-
fection efficiency than PEI at optimized concentration 
reported in the literature in lung epithelial cells, L2, and 
prostate cancer cells, LNCaP. PEI is one of the most efficient 
nonviral vectors and is a standard to which new vectors are 
to bSMCs because this assay is a technique to measure cel-
lular viability in the presence of a foreign substance. 
bSMCs were incubated with various amounts of PSR for 4 
hours, and then MTT assay was preformed to analyze the 
cytotoxic effects of our polymer (FIG. 5). Cells incubated 
with this polymer are 100% viable up to a concentration of 1 
mg/ml. Compared to PEI (25 kD), which has shown to be 
cytotoxic to cells at a concentration as low as 20 µg/ml, PSR 
has demonstrated superior biocompatibility. Also, it has been 
shown poly-arginine peptides are cytotoxic to cells at a level 
20 often compared. Further, PCR exhibited no cytotoxicity even 
at 100 µg/ml, whereas <30% of the cells were viable in the 
presence of 25 µg/ml PEI. 
Other than arginine, side-chain protected lysine can be 
polymerized using the same method. After deprotection, the 
25 resultant polymer with cationic side chains will also serve as 
synthetic vectors for nucleic acid delivery. Oligomers of argi-
nine or lysine and co-oligomers of the two cationic amino 
acids can be polymerized using the same method with poten-
tially greater transfection efficiency. of 5 µM. However, when arginine is incorporated into the backbone of our polymer it results in a biocompatible poly-
mer. One possible reason for the discrepancy between the 30 
toxicities of polyarginine and PSR is that PSR degrades into 
Example 10 
PSR and Heparin Sulfate Matrices a quadrol-like functional group which has been shown to 
promote wound healing. Other arginine-based vectors have 
also been reported having comparable level ofbiocompatibil-
ity. The cytotoxicity profile of PSR signifies its potential as a 35 
safe gene delivery vector. 
PSR (8 mg/ml), heparin sulfate (HS) (10 mg/ml), and 
bFGF (2 ug/ml) were prepared in solutions of D-PBS. The 
amount of PSR used relative to HS was a 35/1 molar ratio. 
Each sample contained 4 mg PSR, 114 µg, and 10 ng ofbFGF. 
The bFGF solution was added to the PSR solution then the HS 
solution was added to the prior mixture. The order of addition 
can be changed. The resultant mixture was agitated and 
Example 9 
In Vitro Transfection 
L2 cells were cultured in 24-well tissue culture treated 
polystyrene plates for at a seeding density of approximately 
40,000 cells per well in 1 mL of Ham's Fl 2k growth medium. 
Cells were grown overnight up to 70% confluency then 
growth medium was replaced with transfections medium. 
Polyplexes were prepared in the same manner as the agarose 
gel retardation assay, but prior to adding the plasmid DNA to 
the PSR solution it was complexed with a DNA intercalating 
agent, YOY0-1. The concentration ofYOY0-1 used for 2 µg 
DNA was 4x 1 o-6 Mand they were incubated at RT for 30 min 
before adding them to PSR solution. The polyplex solution 
was then diluted with serum free medium to a volume of 1 mL 
to form the transfection medium. Various NIP ratios were 
used with a constant amount of DNA, 2 µg, for each well. 
Linear PEI, 25 kD, was used as a positive control and was 
prepared in the same manner as the other polymer solutions. 
Other controls included naked plasmid DNA with and with-
out YOY0-1, YOY0-1, and PSR/YOY0-1. Cells were incu-
bated at 37° C., 5% C02 for 4-5 hand visualized by fluoresce 
using a Nikon Eclipse TE 2000-U microscope equipped with 
a FITC filter. 
40 
allowed to incubate at room temperature for ~ 10 min. The 
mixture was then centrifuged, supernatant was removed, and 
200 µl of D-PBS was added to resuspend the pellet. The 
pellets are ready for release study in PBS. For release in the 
presence of an enzyme, heparinase I (0.01 IU) (IBEX Phar-
45 maceuticals) was added to each sample, and these were 
allowed to incubate at 3 7° C. for 48 h with agitation. Amount 
ofbFGF present after the enzyme digest was quantified using 
a bFGF ELISA kit (R&D Systems). 
For the release profile of bFGF over time, samples were 
50 prepared in the same manner mentioned above (FIG. 9). After 
the resultant mixture was formed samples were incubated at 
37° C. for a specified amount of time: 1, 2, 5, 10, and 15 days. 
At the specified time samples were centrifuged and 300 µl of 
the supernatant was removed and stored at -80° C. The bFGF 
55 concentration in each supernatant was quantified using a 
bFGF ELISA kit. Supernatant was also incubated with 0.001 
IU ofHeparinase I at 37° C. for 48 hand then bFGF concen-
tration was quantified using a bFGF ELISA kit. Controls 
included using PSR and HS without any bFGF present at days 
1and10. 
60 
Example 11 
A gene delivery agent may be able to condense genetic 
information on a nanoscale, but it will be not be viewed as a 
successful delivery vehicle unless it can also transport this 65 
genetic material across the cell membrane. There are different 
techniques employed to measure a vector's ability to trans-
Bioactivity ofbFGEF Contained within PSR/HS 
Nano-Networks 
Micro- to nano-matices were assembled in the same man-
ner as in Example 10 above. After centrifugation 3 ml of 
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bSMC media was added to each well. At the appropriate time 
(24 h & 3 days) media was removed, partitioned, and either 
stored in -80° C. or exposed to a Heparinase I digest as 
mentioned in the release kinetics experiments. bSMCs were 
seeded in 24-well tissue culture treated polystyrene plate at a 
density of approximately 5,000 cells/well over night with 
bSMC media. Smooth cells were then washed twice with 
D-PBS and cultured with bSMC media without growth fac-
tors, bSMC media with control bFGF, and bSMC media with 
bFGF released from matrix. After 24 hand 3 days the smooth 
muscle cells were detached via trypsinization and counted on 
a Coulter Counter. The biological activity of bFGF released 
from nano-matrices was determined by comparing the stimu-
latory effects observed in wells containing control bFGF. 
<160> NUMBER OF SEQ ID NOS, 4 
<210> SEQ ID NO 1 
<211> LENGTH, 5 
<212> TYPE, PRT 
SEQUENCE LISTING 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
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Nano- to micro-networks were prepared with and without 
bFGF and the presence of the growth factor (at such a low 
amount relative to PSR & HS) did not alter the morphology of 
the network. The network was composed of majority of fiber-
like domains along with a minority of globular-like domains. 
Fibers of the networks range from -100 nm to 20 µm and 
globular domains range from 5-20 µm in diameter. The fac-
tors that affect the fiber diameter appeared to include poly-
mer/heparin ratio and solution concentration. 
10 
Statistical Analysis. For each variable group tested there were 
four replicates for the experimental and control samples. 
Multicomparisons ANOVA, Tukey Method, was used to sta-
tistically compare the different experimental values; P<0.05 
was considered statistically significant. The results are 
reported as mean values with standard deviations. 
<223> OTHER INFORMATION, synthetic peptide sequence 
<400> SEQUENCE, 1 
Ile Lys Val Ala Val 
1 5 
<210> SEQ ID NO 2 
<211> LENGTH, 5 
<212> TYPE, PRT 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic peptide sequence 
<400> SEQUENCE, 2 
Tyr Ile Gly Ser Arg 
1 5 
<210> SEQ ID NO 3 
<211> LENGTH, 11 
<212> TYPE, PRT 
<213> ORGANISM: Human immunodeficiency virus 
<400> SEQUENCE, 3 
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 
1 5 10 
<210> SEQ ID NO 4 
<211> LENGTH, 5 
<212> TYPE, PRT 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic peptide sequence 
<400> SEQUENCE, 4 
Gly Arg Glu Asp Val 
1 5 
US 8,529,928 B2 
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What is claimed is: 
1. A polymer comprising repeating units_ according to the 
following formula: 
28 
R3 is selected from the group cons1stmg of alkyl, 
cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and het-
erocycle; and 
wherein n is> 1. 
8. The polymer of claim 7, wherein the diglycidyl ester is 
1,2 cyclohexyldiglycidyl ester. 
9. A method for inducing neurite growth comprising con-
10 tacting neural cells with the polymer of claim 7. 
wherein R1 is any alkyl, cycloalkyl, heterocycloalkyl, aryl, 
heteroaryl, or heterocycle wherein R1 is optionally sub-
stituted with one or more functional group(s) selected 
from the group consisting of halide, alcohol, ether, thio-
ether, tertiary amine, ketone, ester, and amide; 
R2 is any alkyl, cycloalkyl, aryl, or heteroaryl, wherein R2 
15 
10. A method for inducing cell growth or regeneration 
comprising culturing one or more cells on the polymer of 
claim 1. 
11. A method for delivering nucleic acid to a cell compris-
ing packaging the nucleic acid in the polymer of claim 1 and 
contacting the cell with the packaged nucleic acid. 
12. A method for inducing cellular differentiation compris-
is optionally substituted with one or more functional 
group( s) selected from the group consisting of halide, 
alcohol, ether, thioether, tertiary amine, ketone, ester, 
andamide; 20 ing: 
culturing one or more cells on the polymer of claim 1. 
13. A method for delivering a nucleic acid to cell compris-
ing combining the nucleic with the polymer of claim 1 and 
R3 is a biomolecule selected from the group consisting of 
dopamine, glutamate, aspartate, histamine, norepineph-
rine, serotonin, taurine, glycine, 4-aminobutyrate, and 
methionine enkephalin, wherein R3 is bound to R2 via an 
amine bond; and 25 contacting a cell with the combination. 
n is>l. 
2. The polymer of claim 1 that is produced from diglycidyl 
ester which is produced from a dicarboxylic acid. 
3. The polymer of claim 2 wherein the dicarboxylic acid is 
selected from the group consisting of adipic acid, aldaric acid, 30 
aspartic acid, azelaic acid, camphoric acid, dimercaptosuc-
cinic acid, fumaric acid, glutamic acid, glutaric acid, isoph-
thalic acid, itaconic acid, ketoglutaric acid, maleic acid, malic 
acid, malonic acid, mesoxalic acid, n-acetylglutamic acid, 
oxalic acid, oxaloacetic acid, phthalic acid, phthalic acids, 35 
pimelic acid, sebacic acid, suberic acid, succinic acid, tartaric 
acid, terephthalic acid, traumatic acid, dodecanedioic acid, 
chaetomellic acids, ceriporic acids, 1, 2-cyclohexane dicar-
boxylic acid, and 1,4-cyclohexane dicarboxylic acid. 
4. The polymer of claim 1, wherein the polymer is biode- 40 
gradable. 
5. The polymer of claim 1, further comprising an amino 
spacer. 
6. The polymer of claim 1, wherein the polymer promotes 
axon growth relative to a control. 
7. A polymer, produced by condensing monomers of 
dopamine with a diglycidyl ester, having the formula: 
OH 
OH 
wherein R1 and R2 are independently C1 -C18; and 
45 
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14. The polymer of claim 1 having the following structure 
HO 
HO 
15. The polymer of claim 1, wherein n> 1,000. 
16. The polymer of claim 1, wherein n> 10,000. 
17. The polymer of claim 1, wherein n> 100,000. 
* * * * * 
